Circulation

NOVEMBER 11, 2024

Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.

Heart Failure 40

Heart Failure Cardiac Arrest Kidney Disease Atrial Fibrillation 40

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S.,

CME 96

CME Obesity Heart Failure Biomarkers 96

Circulation

NOVEMBER 11, 2024

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among year follow-up time).Results:Among

Diabetes 40

Diabetes Blood Pressure Myocardial Infarction Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001).

Inpatient 40

Inpatient Heart Failure Outcomes Cardiac Arrest 40

Circulation: Heart Failure

MARCH 8, 2024

Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Overt cardiovascular disease, which ranged from 2.1% (HF) to 13.6% (atrial fibrillation), was less common. were female, 25.6% were Black, 12.8%

Heart Failure 40

Heart Failure Atherosclerosis Risk Factors Kidney Disease 40

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes.

Heart attacks 98

Heart attacks Heart Attack Heart Failure Outpatient 98

The British Journal of Cardiology

JULY 17, 2024

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease 52

Kidney Disease Outcomes Diabetes Heart Failure 52

American College of Cardiology

FEBRUARY 12, 2024

What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)

Kidney Disease 56

Kidney Disease Obesity Heart Failure Cardiovascular Disease 56

CardiacWire

OCTOBER 27, 2024

It’s well known that heart disease is the U.S.’s s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. trillion, representing 4.6% of US GDP.

AFIB 59

AFIB Hypertension Kidney Disease Heart Disease 59

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart attacks 81

Heart attacks Heart Attack Heart Failure Outcomes 81

Journal of the American Heart Association

JANUARY 31, 2024

The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all‐cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury.

Kidney Disease 40

Kidney Disease Heart Failure Diabetes Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.

Diabetes 40

Diabetes Stroke Strokes Kidney Disease 40

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

Open Heart

JULY 20, 2022

Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. post-MDT; p<0.001), initiation of renin–angiotensin aldosterone system inhibitors in HF with reduced ejection fraction (HFrEF) with advanced chronic kidney disease (9% pre vs 71% post-MDT; p<0.001).

Heart Failure 52

Heart Failure Kidney Disease Outpatient Nursing 52

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundThis study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).Methods Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94])

Kidney Disease 40

Kidney Disease Diabetes Heart Failure Cardiovascular Disease 40

European Journal of Heart Failure

NOVEMBER 23, 2023

Abstract Aims Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalence and relationship to outcome in ATTR-CA remains unclear.

Kidney Disease 40

Kidney Disease Article Biomarkers Heart Failure 40

Hypertension Journal

OCTOBER 11, 2023

UsingInternational Classification of Disease and Related Health Problems, 10th Revisioncodes, AHT was categorized into 5 spectrums: malignant hypertension (n=1792), hypertensive emergency (n=17 907), hypertensive urgency (n=1562), hypertensive encephalopathy (n=6593), and hypertensive heart failure (HHF;n=22 462).RESULTS:The

Hypertension 40

Hypertension Kidney Disease Heart Failure Risk Factors 40

Cardiometabolic Health Congress

AUGUST 8, 2024

Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

Education 59

Education Cardiovascular Disease Kidney Disease Diabetes 59

Cardiometabolic Health Congress

OCTOBER 10, 2024

Acorai : A heart failure monitoring platform using AI to track and predict patient health. Vitadio : Digital therapeutics for type 2 diabetes and prediabetes, expanding globally. LumineticsCore : An AI diagnostics company with FDA-cleared systems for detecting diabetic retinopathy.

Innovation 52

Innovation Technology Kidney Disease Chronic Disease 52

Circulation

NOVEMBER 11, 2024

Patient did not report any symptoms and was hemodynamically stable.

Bradycardia 40

Bradycardia Coronary Artery Disease Kidney Disease Outpatient 40

Stroke Journal

FEBRUARY 1, 2024

Regarding comorbidities, congestive heart failure (OR 1.73, p &lt;0.01, CI 1.32 to 2.26) and liver disease (OR 2.20, p &lt; 0.01, CI 1.27 Regarding comorbidities, congestive heart failure (OR 1.73, p &lt;0.01, CI 1.32 to 2.26) and liver disease (OR 2.20, p &lt; 0.01, CI 1.27

Inpatient 40

Inpatient Stroke Strokes Coronary Artery Disease 40

DAIC

SEPTEMBER 11, 2024

A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

DAIC

SEPTEMBER 11, 2024

A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

Open Heart

JULY 10, 2023

Higher-predicted risk, compared with lower-predicted risk, was associated with incident chronic kidney disease (cumulative incidence per 1000 persons at 10 years 245.2; years), heart failure (124.7; to 13.01; 4.06), diabetes mellitus (123.3; to 5.22; 4.32), peripheral vascular disease (44.6; 12.54, 12.08

Atrial Fibrillation 52

Atrial Fibrillation Myocardial Infarction Kidney Disease Innovation 52

Journal of Cardiovascular Electrophysiology

NOVEMBER 5, 2023

Results Compared to patients in early CBA group, patients in late CBA group had higher prevalence of diabetes, congestive heart failure, and chronic kidney disease, and higher mean CHA 2 DS 2 -VAS score. The primary outcome was recurrence of atrial tachyarrhythmias (ATs) of ≥30-s after a 3-month blanking period.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Kidney Disease 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Circulation: Cardiovascular Imaging

JANUARY 15, 2024

BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. METHODS:We retrospectively followed patients who underwent MPI before kidney transplant for the occurrence of MACE after transplant including myocardial infarction, stroke, heart failure, and cardiac death.

Transplant 40

Transplant Coronary Artery Disease Myocardial Infarction Kidney Disease 40

DAIC

JANUARY 19, 2024

This leaves a gap in the care of these patients and increases their risk for heart attack, stroke and heart failure progression. HTN accelerates the progression of atherosclerosis and leads to increased risk of major cardiac events like heart attack, heart failure, kidney disease and other end organ damage.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

All About Cardiovascular System and Disorders

OCTOBER 25, 2023

AF-CHF trial in those with AF and congestive heart failure also failed to show any advantage for the rhythm control strategy [3]. Overall, it appears that rhythm control strategy in AF may be better in those with heart failure and in those with associated cardiovascular conditions and early AF.

Atrial Fibrillation 52

Atrial Fibrillation Heart Failure Ablation Cardiac Arrest 52

European Journal of Heart Failure

DECEMBER 12, 2023

Background Anemia and ID are common comorbidities in cardiovascular patients and are associated with a poor clinical status, as well as a worse outcome in patients with heart failure and AMI. Nevertheless, data concerning the impact of anemia and ID on clinical outcome in patients with CS are scarce.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes Catheterization Laboratory 40

DAIC

DECEMBER 8, 2023

AFib causes a variety of symptoms, including fast or chaotic heartbeat, fatigue, shortness of breath, and chest pain, and causes about 450,000 hospitalizations each year, according to the Centers for Disease Control and Prevention. For example, kidney disease is not included in CHA 2 DS 2 -VASc.

Atrial Fibrillation 52

Atrial Fibrillation AFIB Stroke Strokes 52

Circulation

NOVEMBER 11, 2024

It is highly recommended to screen for liver fibrosis in patients with Type 2 diabetes mellitus (T2DM) and elevated liver enzymes using the fibrosis-4 (FIB-4) score.However, this recommendation does not extend to patients with chronic heart failure (CHF) who do not have T2DM. 1.45), cardiovascular mortality (HR: 1.80, 95% CI: 1.49-2.17),

Heart Failure 40

Heart Failure Diabetes Myocardial Infarction Kidney Disease 40

Open Heart

SEPTEMBER 27, 2023

Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.

Risk Factors 52

Risk Factors Kidney Disease Heart Failure Diabetes 52

Journal of the American Heart Association

JANUARY 23, 2024

BackgroundThe relation between age at diagnosis of type 2 diabetes (T2D) and hospitalization for heart failure (HHF) is unclear. We identified people with new‐onset T2D between April 1, 2005 and March 31, 2015, and matched each person with 3 diabetes‐free adults, according to birth year and sex.

Heart Failure 40

Heart Failure Diabetes Hospital Coronary Artery Disease 40

Open Heart

JULY 6, 2023

Background Chronic kidney disease (CKD) and atrial fibrillation (AF) are increasing in prevalence globally and share common risk factors. Age, sex, diabetes, hypertension and heart failure were chosen as variables of interest. Methods PubMed, EMBASE and CINAHL were searched from inception to June 2022.

Kidney Disease 52

Kidney Disease Atrial Fibrillation Heart Failure Risk Factors 52